SCHEMBL1195656

SCHEMBL1195656

O=C(O)/C=C/c1cc(F)cc(F)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 2/20 0.53
HCAR2 Q8TDS4 3/20 0.52
HDAC3 O15379 2/20 0.52
HDAC4 P56524 2/20 0.52
HDAC1 Q13547 2/20 0.52
HDAC7 Q8WUI4 2/20 0.52
HDAC2 Q92769 2/20 0.52
HDAC10 Q969S8 2/20 0.52
HDAC11 Q96DB2 2/20 0.52
HDAC8 Q9BY41 2/20 0.52
HDAC6 Q9UBN7 2/20 0.52
HDAC9 Q9UKV0 2/20 0.52
HDAC5 Q9UQL6 2/20 0.52
TNKS O95271 1/20 0.52
TNKS2 Q9H2K2 1/20 0.52
KDM4E B2RXH2 3/20 0.48
HSD17B10 Q99714 3/20 0.48
ALDH1A1 P00352 2/20 0.48
HPGD P15428 2/20 0.48
PKM P14618 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL188332 1.00 BACE1 (0.53) BACE1HCAR2HDAC3HDAC4HDAC1
Hydrochloric Acid SCHEMBL6821858 0.98 BACE1 (0.51) BACE1HCAR2HDAC3HDAC4HDAC1
Guanidine SCHEMBL7172098 0.89 BACE1 (0.45) BACE1HCAR2HDAC3HDAC4HDAC1
SCHEMBL9367430 0.86 AKR1C3 (0.46) BACE1HCAR2HDAC3HDAC4HDAC1
SCHEMBL4716666 0.86 HDAC3 (0.44) BACE1HCAR2HDAC3HDAC4HDAC1
SCHEMBL26969012 0.86 NPSR1 (0.56) BACE1HCAR2HDAC3HDAC4HDAC1
SCHEMBL9367435 0.86 AKR1C3 (0.46) BACE1HCAR2HDAC3HDAC4HDAC1
SCHEMBL4716668 0.86 HDAC3 (0.44) BACE1HCAR2HDAC3HDAC4HDAC1
SCHEMBL20475290 0.86 HCAR2 (0.44) BACE1HCAR2HDAC3HDAC4HDAC1
SCHEMBL3930273 0.83 CYP1A2 (0.43) BACE1HCAR2HDAC3HDAC4HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 345 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4661890-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS Purdue Research Foundation (US) 2025-12-17 EP claimed
US-12365830-B2 Ligand-exchangeable janus nanoparticles and methods of making the same ALLIANCE FOR SUSTAINABLE ENERGY, LLC (US) 2025-07-22 US claimed
CN-118930859-A Cinnamic acid modified polyarylene sulfide and preparation method thereof 新凝合科技(成都)有限公司 2024-11-12 CN claimed
WO-2024167565-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS PURDUE RESEARCH FOUNDATION (US) 2024-08-15 WO claimed
US-20220259490-A1 LIGAND-EXCHANGEABLE JANUS NANOPARTICLES AND METHODS OF MAKING THE SAME Alliance for Energy Innovation, LLC 2022-08-18 US claimed
WO-2020252075-A1 LIGAND-EXCHANGEABLE JANUS NANOPARTICLES AND METHODS OF MAKING THE SAME ALLIANCE FOR SUSTAINABLE ENERGY, LLC (US) 2020-12-17 WO claimed
US-10544168-B2 Ligand-exchangeable nanoparticles and methods of making the same ALLIANCE FOR SUSTAINABLE ENERGY, LLC (US) 2020-01-28 US claimed
US-10072043-B2 Inhibitors of protein tyrosine phosphatases INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2018-09-11 US claimed
US-20170362255-A1 LIGAND-EXCHANGEABLE NANOPARTICLES AND METHODS OF MAKING THE SAME Alliance for Energy Innovation, LLC 2017-12-21 US claimed
US-20160176922-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES Indiana University Research and Technology Corpora tion (US) 2016-06-23 US claimed
US-7311767-B2 Forming a salt of a liquid phase change ink carrier of stearyl stearamide, an amine substituted Xanthene, acridine, anthracene or thioxanthene chromogen, and a metal salt capable of forming a compound with two chromogens XEROX CORPORATION (US) 2007-12-25 US claimed
EP-1747059-A1 PERVAPORATION COMPOSITE MEMBRANES McMaster University (CA) 2007-01-31 EP claimed
US-7033424-B2 Phase change inks XEROX CORPORATION (US) 2006-04-25 US claimed
US-20060021546-A1 Processes for preparing phase change inks XEROX CORPORATION 2006-02-02 US claimed
US-20060020141-A1 Metallized dye XEROX CORPORATION 2006-01-26 US claimed
US-20060016369-A1 PHASE CHANGE INKS XEROX CORPORATION 2006-01-26 US claimed
US-20060000778-A1 high-performance membrane designed for the selective removal of a polar fluid (water) from less polar fluids (organic solvents), by a pervaporation using a composite membrane contaiing ultrafiltration membrane as support ( e.g. cellulose acetate) and a crosslinked copolymer of anionic, cationic monomers MCMASTER UNIVERSITY (CA) 2006-01-05 US claimed
WO-2005102503-A1 PERVAPORATION COMPOSITE MEMBRANES MCMASTER UNIVERSITY (CA) 2005-11-03 WO claimed
US-6946025-B2 Process for preparing tetra-amide compounds XEROX CORPORATION (US) 2005-09-20 US claimed
US-20050090690-A1 Process for preparing tetra-amide compounds XEROX CORPORATION 2005-04-28 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10544168-B2 Ligand-exchangeable nanoparticles and methods of making the same CA6, CA13, EPCAM BACE1 3605/4885HCAR2 11/4885HDAC3 2613/4885
US-10072043-B2 Inhibitors of protein tyrosine phosphatases PTPRCAP, PTPRF, PTPRS BACE1 4548/4885HCAR2 4789/4885HDAC3 3090/4885
US-20160176922-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES PTPRCAP, PTPRF, PTPRS BACE1 4548/4885HCAR2 4789/4885HDAC3 3090/4885
US-20060020141-A1 Metallized dye CDYL, CDY1; CDY1B, CDYL2 BACE1 2312/4885HCAR2 3310/4885HDAC3 1033/4885
US-20050090690-A1 Process for preparing tetra-amide compounds TAF9, TAF5, TAF1 BACE1 4804/4885HCAR2 2828/4885HDAC3 849/4885
US-20170362255-A1 LIGAND-EXCHANGEABLE NANOPARTICLES AND METHODS OF MAKING THE SAME CA6, CA13, EPCAM BACE1 3605/4885HCAR2 11/4885HDAC3 2613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.